IMR Press / CEOG / Volume 46 / Issue 4 / DOI: 10.12891/ceog4532.2019

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Leukemia inhibitory factor, glycodelin, and HOXA-10 in gestational diabetes
Show Less
1 Obstetrics and Gynecology, Medicana Hospital, Istanbul, Turkey
2 Obstetrics and Gynecology, Cerrahpasa Medical Faculty, Istanbul, Turkey
3 Histopatholoy, Cerrahpasa Medical Faculty, Istanbul, Turkey
4 Obstetrics and Gynecology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
*Correspondence: dryavuzaydin@gmail.com (YAVUZ AYDIN)
Clin. Exp. Obstet. Gynecol. 2019, 46(4), 539–541; https://doi.org/10.12891/ceog4532.2019
Published: 10 August 2019
Abstract

Purpose of investigation: The authors aimed to localize glycodelin, leukemia inhibitory factor (LIF), and HOXA-10 in term placentas and study the relationship between these markers and maternal gestational diabetes. Materials and Methods: Following labor, placentas from 12 pregnant women with gestational diabetes and 15 healthy pregnant women were collected, fixed, and paraffin-embedded, and immunohistochemical studies were performed. Two independent researchers examined the specimens under light microscopy. Immunoreactive scores were calculated and compared. Results: Glycodelin and HOXA-10 were stained in the decidua, and LIF was stained both in the trophoblast and in the decidua of term placentas. The three markers’ immunoreactive scores were not different between pregnant women with gestational diabetes and the healthy controls. Conclusion: Glycodelin and HOXA-10 were produced by maternal decidual cells; LIF was produced by both trophoblasts and maternal decidual cells. Glycodelin, HOXA-10, and LIF are not related to the pathophysiology of gestational diabetes.

Keywords
Gestational diabetes
Glycodelin
HOXA-10
Leukemia inhibitory factor
Share
Back to top